Patient-friendly peptide education
General peptide therapy, clinics, safety, brands and long-tail topics.
Recently published
Goop Peptide Dupe My Practical Reflections On Exploratory Testing of Goop Peptide Dupe Rational design built on molecular recognition principles enables researchers to construct peptide modules for specific bi…
Read guide →Data showed IL-1β-targeting mAb led to up to 100% improvement in symptoms. Novartis reported positive results from the first Phase III study to evaluate its IL-1β-targeting mAb, ACZ885 (canakinumab), in patien…
Read guide →The Peptide University The Peptide University:A Lab Manual for Blending and Compatibility Historical patterns in peptide research demonstrate how innovation in one area often stimulates progress in related fie…
Read guide →Drug given once a week lowered HbA1c more than Byetta administered twice a day. Roche reports that its type 2 diabetes drug, taspoglutide, showed better reduction of HbA1c levels compared to Lilly’s Byetta. Th…
Read guide →Il Peptide Il Peptide Reading:Academic Review Of Multi-Year Research Results Public awareness of peptide molecule stability has improved through educational campaigns by research institutions in recent years. …
Read guide →Peptide C Ecn Understanding Peptide C Ecn:Practical Insights on Storage Temperature Successive waves of technological advancement have, over time, transformed peptide synthesis from a specialized craft into a …
Read guide →Approval is reportedly the first to allow dosing every two years. FDA approved Novartis’ Reclast(r) as the first two-yearly treatment for the prevention of postmenopausal osteoporosis. The agency based its app…
Read guide →Whereas we mostly tend to think of arthritis as an old person’s disease, there is a form of it that affects children—and those kids now have a reason to jump for joy. The FDA just approved Novartis’ Ilaris® (c…
Read guide →Metal Peptide Complex Metal Peptide Complex and the Importance of Individual System Variability Historical patterns in peptide research demonstrate how innovation in one area often stimulates progress in relat…
Read guide →The European Commission approved the Vertex Pharmaceuticals drug Kalydeco™ (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibro…
Read guide →Grc Peptides 2025 Grc Peptides 2025 Demystified:Multi-Dimensional Interpretation Of Basic Traits Comprehensive market analysis reveals accelerating adoption of synthetic peptides across pharmaceutical and cosm…
Read guide →Wolverine Peptide Frequency Deconstructing Wolverine Peptide Frequency:Molecular Behavior in Serum-Free Media A deeper understanding of side-chain protection mechanisms supports safer handling of peptide molec…
Read guide →The FDA has issued final guidance for biopharmas seeking to incorporate what the agency deems “promising emerging and novel technologies” in their drug manufacturing processes. The final guidance, titled “Adva…
Read guide →Sponsored content brought to you by Even with standard methods of care, 55% of the 2 million people diagnosed with cancer this year will unfortunately pass. With this devastating statistic in mind, researchers…
Read guide →Peptide Stock Photos What's New with Peptide Stock Photos: My Take on Scalable Peptide Production Global market interest in stabilized peptide formulations has expanded across several pharmaceutical and cosmet…
Read guide →$900,000 over two years will go toward enhancing the peptide manufacturing and delivery technologies. Unigene Laboratories received a $900,000 funding to advance it’s discovery program related to therapeutic p…
Read guide →Cells That Respond To Peptide Hormones Usually Do So Through Mapping Cells That Respond To Peptide Hormones Usually Do So Through:Signaling Logic in Skin Barrier Models Data-driven experimental design accelera…
Read guide →Collaboration will focus on tau-related AD and will leverage Bayer’s imaging tools. TauRx Pharmaceuticals and Bayer Schering Pharma (BSP) are allying to develop diagnostics for Alzheimer disease (AD) treatment…
Read guide →Agreement initially covers BI’s registrational linagliptin, an SGLT-2 blocker, and two Lilly basal insulin analogues. Lilly is paying Boehringer Ingelheim (BI) €300 million (about $402 million) up front to sea…
Read guide →Dual-mechanism oral small molecule MBX-2982 acts as GPR119 agonist. Sanofi-Aventis negotiated a global license and development agreement with Metabolex centered on small molecule type 2 diabetes therapies that…
Read guide →Browse by subject
Each topic opens a crawlable collection of related articles and resources.